ArticleJournal of translational medicine2025
Distinct platelet transcriptomic heterogeneity in respiratory illnesses and modulation by corticosteroids and immune antibody treatments.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCirculating platelets are increasingly recognized for their critical involvement in thromboinflammatory complications during respiratory infections, underscoring the importance of comprehending their dual role in immunomodulation and hemostasis. The multifaceted roles of platelets are attributed to their inherent heterogeneity, where the molecular diversity enables their functional versatility. However, research remains deficient in dissecting platelet heterogeneity within respiratory infection contexts, capturing the platelet subpopulations exhibiting specialized functional roles, and elucidating the therapeutic modulation by dexamethasone and tocilizumab.
methodsLeveraging the adequate platelet population detected through single-cell RNA sequencing, this study established stratified study cohorts central to: (1) COVID-19 disease severity, (2) therapeutic responsiveness, and (3) non-COVID-19 respiratory infections. An integrative annotation framework was implemented in this study, which encompassed co-expressed gene module identification, cell-cell communication network mapping, and cell trajectory assessment, to hierarchically dissect the functional dynamics of platelet heterogeneity in disease pathologies and their modulation by therapeutic interventions.
resultsThis study unfolds six severity-associated platelet subpopulations, explores their modulation by corticosteroids and immune antibody treatments, and extends the findings to non-COVID-19 severe conditions. In severe COVID-19, platelet subpopulations with elevated innate immune responsiveness and high coagulation potential are intensively enriched, whereas following dexamethasone administration, this pro-coagulable subpopulation is remarkably repressed. Post-tocilizumab treatment, the instructive interaction from platelets to IFN-activated CD8
conclusionsA systematic investigation of platelet transcriptomic heterogeneity in respiratory infections, combined with the delineation of its therapeutic modulation by dexamethasone and tocilizumab, advances the understanding of platelet involvement in immune-thrombotic dysregulation and provides a foundation for exploring potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.